{
    "hands_on_practices": [
        {
            "introduction": "In clinical genetics, a test's accuracy, defined by its sensitivity and specificity, can be misleading if not interpreted in context. This exercise explores the crucial concept of Positive Predictive Value (PPV), which answers the patient's most urgent question: \"Given a positive test result, what is the actual probability that I (or my fetus) has the condition?\" By working through a realistic scenario involving non-invasive prenatal testing (NIPT), you will see how a condition's low prevalence can dramatically affect the meaning of a positive screen, a statistical reality with profound implications for ethical patient counseling .",
            "id": "5028518",
            "problem": "A clinician is counseling a patient who has received a positive result for trisomy 21 on Non-Invasive Prenatal Testing (NIPT; Non-Invasive Prenatal Testing). The test characteristics in the screened population are sensitivity 0.99, specificity 0.999, and the prevalence of trisomy 21 is 0.001. Using only fundamental definitions of sensitivity, specificity, prevalence, and conditional probability, derive an expression for the positive predictive value (PPV), which is the probability that the fetus actually has trisomy 21 given a positive NIPT result. Then compute the PPV for these parameters. Express the PPV as a decimal (not with a percentage sign) and round your final numeric answer to four significant figures. Finally, briefly explain how this PPV should inform pre-test and post-test counseling in terms of autonomy, beneficence, and the need for confirmatory diagnostic testing.",
            "solution": "The problem as stated is scientifically grounded, well-posed, and objective. It presents a standard application of Bayesian statistics to evaluate the performance of a medical screening test. All necessary parameters (sensitivity, specificity, prevalence) are provided, and their values are realistic for the clinical context of Non-Invasive Prenatal Testing (NIPT) for trisomy 21. The problem is therefore valid.\n\nWe begin by formally defining the events and probabilities involved.\nLet $D$ be the event that the fetus has trisomy 21 (the \"disease\" is present).\nLet $D^c$ be the event that the fetus does not have trisomy 21.\nLet $T^+$ be the event that the NIPT result is positive.\nLet $T^-$ be the event that the NIPT result is negative.\n\nFrom the problem statement, we are given the following values:\nThe prevalence of trisomy 21 is the prior probability of the condition, $P(D) = 0.001$.\nThe sensitivity of the test is the probability of a positive result given that the disease is present, $P(T^+ | D) = 0.99$.\nThe specificity of the test is the probability of a negative result given that the disease is absent, $P(T^- | D^c) = 0.999$.\n\nWe are asked to derive an expression for the positive predictive value (PPV), which is defined as the probability that the fetus actually has trisomy 21 given a positive test result. In probabilistic terms, this is the conditional probability $P(D | T^+)$.\n\nWe will use Bayes' theorem to find this value. The theorem states:\n$$\nP(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)}\n$$\nThe numerator contains terms that are directly given or can be derived immediately. We have $P(T^+ | D) = 0.99$ (sensitivity) and $P(D) = 0.001$ (prevalence).\n\nThe denominator, $P(T^+)$, is the total probability of receiving a positive test result. This can be calculated using the law of total probability, which involves marginalizing over the disease status:\n$$\nP(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)\n$$\nLet's analyze the terms in this expansion:\n$P(T^+ | D)$ is the sensitivity, given as $0.99$.\n$P(D)$ is the prevalence, given as $0.001$.\n$P(D^c)$ is the probability that the fetus does not have trisomy 21. Since this is the complement of having the disease, $P(D^c) = 1 - P(D) = 1 - 0.001 = 0.999$.\n$P(T^+ | D^c)$ is the probability of a positive test in an unaffected fetus. This is the false positive rate. It is the complement of the specificity, since specificity, $P(T^- | D^c)$, is the probability of a true negative. Thus, $P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - \\text{specificity}$. In this case, $P(T^+ | D^c) = 1 - 0.999 = 0.001$.\n\nNow, let's substitute these terms into the formula for $P(T^+)$:\n$$\nP(T^+) = (0.99)(0.001) + (1 - 0.999)(1 - 0.001)\n$$\nSubstituting this expanded form of $P(T^+)$ back into the Bayes' theorem expression for PPV, we obtain the general formula for PPV in terms of sensitivity (sens), specificity (spec), and prevalence (prev):\n$$\n\\text{PPV} = P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)} = \\frac{(\\text{sens})(\\text{prev})}{(\\text{sens})(\\text{prev}) + (1 - \\text{spec})(1 - \\text{prev})}\n$$\nThis is the derived expression for the positive predictive value.\n\nNext, we compute the numerical value for the PPV using the given parameters:\n$\\text{sens} = 0.99$\n$\\text{spec} = 0.999$\n$\\text{prev} = 0.001$\n\nSubstituting these values into our derived formula:\n$$\n\\text{PPV} = \\frac{(0.99)(0.001)}{(0.99)(0.001) + (1 - 0.999)(1 - 0.001)}\n$$\n$$\n\\text{PPV} = \\frac{0.00099}{0.00099 + (0.001)(0.999)}\n$$\n$$\n\\text{PPV} = \\frac{0.00099}{0.00099 + 0.000999}\n$$\n$$\n\\text{PPV} = \\frac{0.00099}{0.001989}\n$$\n$$\n\\text{PPV} \\approx 0.497737556...\n$$\nThe problem requires the final numeric answer to be rounded to four significant figures.\n$$\n\\text{PPV} \\approx 0.4977\n$$\nThis result is profoundly important for clinical counseling. The calculated PPV of approximately $0.4977$ indicates that for a patient in this population who receives a positive NIPT result, there is only a $49.77\\%$ chance that the fetus actually has trisomy 21. Conversely, there is a $100\\% - 49.77\\% = 50.23\\%$ chance that the result is a false positive. This counter-intuitive outcome, where a test with high sensitivity ($99\\%$) and specificity ($99.9\\%$) yields a positive result that is more likely to be false than true, is a classic illustration of the effect of low prevalence on predictive values (an instance of the base rate fallacy).\n\nThis calculated PPV has direct implications for counseling based on core ethical principles:\n1.  **Autonomy**: Pre-test counseling must stress that NIPT is a *screening* test, not a diagnostic one. The clinician must explain that a positive result does not confirm the diagnosis but rather indicates an increased risk. By providing the patient with an accurate understanding of what the test can and cannot do, including the concept of PPV, the clinician empowers the patient to make an autonomous and informed decision about whether to proceed with screening. Post-test counseling for a positive result must quantitatively explain the PPV (i.e., \"There is about a 50-50 chance this result is a true positive\"). This allows the patient to weigh their personal values and decide on subsequent steps, such as confirmatory diagnostic testing, without undue panic or coercion.\n2.  **Beneficence and Non-maleficence**: The principle of beneficence (acting in the patient's best interest) and non-maleficence (avoiding harm) compels the clinician to prevent the harm that could arise from misinterpreting a positive NIPT result as a definitive diagnosis. Such a misunderstanding could cause severe psychological distress and could lead to irreversible decisions, such as pregnancy termination, based on a probabilistic screening result. By clearly communicating that the PPV is only about $50\\%$, the clinician acts to prevent this harm and ensures patient well-being.\n3.  **Need for Confirmatory Diagnostic Testing**: The fact that the PPV is significantly below $1.0$ (and in this case, below $0.5$) is the quantitative justification for recommending confirmatory diagnostic testing. Tests like amniocentesis or chorionic villus sampling (CVS) provide a definitive karyotype with much higher accuracy, though they carry a small risk of procedural complications. The low PPV of the screening test makes the risk-benefit analysis of an invasive diagnostic test favorable for a patient seeking diagnostic certainty. Counseling must frame confirmatory testing as the necessary next step to resolve the uncertainty created by the positive NIPT screen before any definitive clinical conclusions are drawn or irreversible decisions are made.",
            "answer": "$$\n\\boxed{0.4977}\n$$"
        },
        {
            "introduction": "The fear that genetic information could be used to discriminate in employment or insurance is a significant barrier to the uptake of genetic testing. This problem requires you to act as a legal analyst, dissecting the complex, overlapping protections offered by key pieces of U.S. legislation: the Genetic Information Nondiscrimination Act (GINA), the Americans with Disabilities Act (ADA), and the Affordable Care Act (ACA). Mastering the critical distinction between protections for genetic risk versus a manifested disease is an essential skill for anyone advising patients or formulating policy in the genomic era .",
            "id": "5028553",
            "problem": "An advanced genomics clinic is training counselors to advise clients on legal protections surrounding genetic information and disease. The training emphasizes reasoning from statutory purpose and core definitions in United States law: that the Genetic Information Nondiscrimination Act (GINA) regulates the use of genetic information, the Americans with Disabilities Act (ADA) regulates discrimination based on disability in employment, and the Affordable Care Act (ACA) regulates health insurance practices including preexisting condition exclusions and health status underwriting. Counselors must distinguish protections that attach to genetic risk (e.g., an asymptomatic pathogenic variant) versus protections that attach to manifest disease (e.g., a current diagnosis with symptoms), and understand sector-specific scope (employment versus health insurance versus life insurance).\n\nYou are asked to evaluate the following statements for correctness. Your task is to select all statements that accurately contrast the protections offered by GINA with those under the ADA and the ACA, and that correctly describe their distinct applicability to genetic risk versus manifest disease.\n\nA. In employment, GINA’s nondiscrimination provisions apply to genetic information such as genetic test results and family history, but discrimination based solely on a current diagnosis is not “genetic information”; when a genetic condition is manifested, the ADA, rather than GINA, is the principal law prohibiting discrimination and requiring reasonable accommodation if the impairment substantially limits a major life activity.\n\nB. For health insurance, the ACA bars denying coverage, imposing preexisting condition exclusions, or health-status underwriting for both genetic risk and manifest disease; by contrast, GINA’s health insurance provisions specifically prohibit requesting or using genetic information for underwriting and eligibility, but by themselves do not address underwriting based on a current diagnosis.\n\nC. GINA prohibits life, disability, and long-term care insurers from requesting or using genetic test results, so consumers with pathogenic variants but no symptoms are protected across those markets.\n\nD. The ADA protects asymptomatic carriers of pathogenic variants because they are “regarded as” disabled and therefore obligates employers to provide reasonable accommodations to prevent potential future impairment even in the absence of current limitation.\n\nE. The ACA allows health insurers to collect genetic information for underwriting as long as they do not deny coverage on that basis; GINA, by contrast, prohibits collection of genetic information for underwriting but permits its use if voluntarily provided by the applicant.\n\nF. ADA protections apply only to employers with at least 15 employees, whereas GINA’s employment provisions apply to all employers regardless of size.\n\nSelect all that apply.",
            "solution": "The problem asks for an evaluation of several statements describing the legal protections afforded by the Genetic Information Nondiscrimination Act (GINA), the Americans with Disabilities Act (ADA), and the Affordable Care Act (ACA) in the United States, specifically concerning the distinction between genetic risk and manifest disease in different sectors. The problem statement is valid as it is grounded in established legal and scientific principles, is well-posed, objective, and requires a nuanced understanding of real-world statutes.\n\nWe will proceed with a detailed analysis of each option.\n\nA. **In employment, GINA’s nondiscrimination provisions apply to genetic information such as genetic test results and family history, but discrimination based solely on a current diagnosis is not “genetic information”; when a genetic condition is manifested, the ADA, rather than GINA, is the principal law prohibiting discrimination and requiring reasonable accommodation if the impairment substantially limits a major life activity.**\n\nThis statement accurately delineates the respective domains of GINA and the ADA in the employment context.\n- **GINA's Scope in Employment:** Title II of GINA prohibits employers from discriminating against employees or applicants based on their \"genetic information.\" The law defines \"genetic information\" to include an individual's genetic tests, the genetic tests of family members, and the manifestation of a disease or disorder in family members (i.e., family medical history).\n- **GINA's Manifest Disease Exclusion:** A crucial element of GINA is that it explicitly excludes a manifested disease or disorder from the definition of \"genetic information.\" Therefore, if an employer discriminates against an individual because they are currently sick, that action is not prohibited by GINA, even if the sickness has a genetic basis.\n- **ADA's Role:** The ADA prohibits discrimination on the basis of \"disability.\" A manifested genetic condition that substantially limits one or more major life activities qualifies as a disability under the ADA. Thus, the ADA provides protection where GINA's protection ends. The ADA also mandates that employers provide \"reasonable accommodations\" for qualified individuals with disabilities, a provision not found in GINA.\nThis statement correctly captures this critical hand-off from GINA (protecting against discrimination based on future risk) to the ADA (protecting against discrimination based on current disability).\n\nVerdict: **Correct**.\n\nB. **For health insurance, the ACA bars denying coverage, imposing preexisting condition exclusions, or health-status underwriting for both genetic risk and manifest disease; by contrast, GINA’s health insurance provisions specifically prohibit requesting or using genetic information for underwriting and eligibility, but by themselves do not address underwriting based on a current diagnosis.**\n\nThis statement correctly contrasts the protections of the ACA and GINA in the health insurance market.\n- **ACA's Protections:** The ACA instituted broad reforms, most notably prohibiting health insurers in the individual and group markets from denying coverage, charging higher premiums, or imposing preexisting condition exclusions based on an individual's health status. \"Health status\" is a wide-ranging term that encompasses both manifest diseases (current conditions) and genetic predispositions to disease (genetic risk).\n- **GINA's Protections in Health Insurance:** Title I of GINA is more specific. It prohibits group and individual health insurers from using an individual's genetic information to make underwriting decisions (e.g., setting premiums) or for eligibility determinations. It also prohibits them from requesting or requiring an individual to undergo a genetic test. Like its employment provisions, GINA's health insurance protections do not apply to a manifested disease.\nThe statement accurately portrays the ACA as providing a broad protective floor for all health conditions (risk and manifest disease), while GINA provides targeted, and in some ways more stringent, protections specifically for genetic information (e.g., a prohibition on even requesting the information for underwriting purposes), while not covering discrimination based on a current diagnosis.\n\nVerdict: **Correct**.\n\nC. **GINA prohibits life, disability, and long-term care insurers from requesting or using genetic test results, so consumers with pathogenic variants but no symptoms are protected across those markets.**\n\nThis statement is factually incorrect. GINA's provisions apply only to health insurance (Title I) and employment (Title II). The law explicitly does not extend to other forms of insurance, such as life insurance, disability insurance, or long-term care insurance. Insurers in these markets are generally permitted under federal law to request and use genetic information, including genetic test results, in their underwriting processes. This is a widely recognized limitation of GINA.\n\nVerdict: **Incorrect**.\n\nD. **The ADA protects asymptomatic carriers of pathogenic variants because they are “regarded as” disabled and therefore obligates employers to provide reasonable accommodations to prevent potential future impairment even in the absence of current limitation.**\n\nThis statement contains a critical legal error. The ADA defines disability in three ways: (1) a physical or mental impairment that substantially limits one or more major life activities (an \"actual\" disability); (2) a record of such an impairment; or (3) being \"regarded as\" having such an impairment. While an asymptomatic carrier might be protected under the \"regarded as\" prong if their employer mistakenly believes their genetic status is a current, limiting impairment, the law is explicit on the matter of accommodations. The ADA Amendments Act of 2008 (ADAAA) clarifies that an employer is **not** required to provide a reasonable accommodation to an individual who meets only the \"regarded as\" definition of disability. The obligation to provide reasonable accommodation applies only to individuals with an actual disability or a record of one. The statement's claim that \"regarded as\" status obligates an employer to provide accommodations is a direct contradiction of the statute.\n\nVerdict: **Incorrect**.\n\nE. **The ACA allows health insurers to collect genetic information for underwriting as long as they do not deny coverage on that basis; GINA, by contrast, prohibits collection of genetic information for underwriting but permits its use if voluntarily provided by the applicant.**\n\nThis statement misrepresents both the ACA and GINA.\n- **ACA:** The ACA prohibits health-status underwriting in most markets. While it may not have an explicit \"thou shalt not collect\" provision like GINA, its ban on the *use* of such information for underwriting effectively renders its collection for that purpose prohibited. The premise that the ACA \"allows\" this collection for underwriting is misleading and functionally incorrect.\n- **GINA:** GINA prohibits health insurers from *using* genetic information for underwriting purposes, regardless of whether it was requested or provided voluntarily. If an insurer comes into possession of genetic information (e.g., it is included in a medical record provided by the applicant), the insurer is still barred from using it to set premiums or determine eligibility. The statement's claim that GINA \"permits its use if voluntarily provided\" is false.\n\nVerdict: **Incorrect**.\n\nF. **ADA protections apply only to employers with at least 15 employees, whereas GINA’s employment provisions apply to all employers regardless of size.**\n\nThis statement incorrectly describes the scope of GINA. Title I of the ADA, which covers employment, applies to employers with 15 or more employees. Title II of GINA, which covers employment, was designed to be consistent with the scope of other federal anti-discrimination laws, including the ADA. Therefore, GINA's employment provisions also apply only to employers with 15 or more employees. The statement's claim that GINA applies to all employers regardless of size is false.\n\nVerdict: **Incorrect**.",
            "answer": "$$\\boxed{AB}$$"
        },
        {
            "introduction": "Genomic research promises to revolutionize medicine, but it relies on sharing vast datasets, raising critical privacy concerns. This exercise delves into the technical and ethical challenges of data de-identification using the concept of $k$-anonymity. You will first calculate the theoretical privacy guarantee it provides and then explore how this protection can be compromised by linkage attacks, demonstrating the inherent tension between fostering open science and upholding the duty to protect participant confidentiality .",
            "id": "5028499",
            "problem": "A university medical center plans to publicly release a de-identified research dataset of 10,000 adult participants enrolled in a cardiovascular genomics study. For each participant, the dataset includes a polygenic risk score for coronary artery disease and the following quasi-identifiers: age in years, sex, and the three-digit postal code prefix (ZIP$3$). Before release, the center applies $k$-anonymity with $k=20$ on the quasi-identifiers so that every combination of age, sex, and ZIP$3$ appearing in the dataset occurs in at least 20 records.\n\nUsing only fundamental definitions, proceed as follows:\n\n1) Starting from the definition that $k$-anonymity partitions records into equivalence classes of size at least $k$ based on the quasi-identifiers, and the prosecutor threat model in which an adversary knows that a specific target individual is in the dataset and knows the target’s quasi-identifiers, derive the tightest upper bound on the per-individual re-identification probability for such an adversary in terms of $k$.\n\n2) Evaluate your bound for $k=20$ and express the result as a decimal number (do not use a percent sign). Because the bound for $k=20$ is exact, no rounding is necessary.\n\n3) Briefly explain, using the same foundational definitions, how linkage to external registries containing age, sex, and ZIP$3$ could increase the re-identification risk by effectively altering equivalence class sizes, and how this relates to the ethical, legal, and social implications of genomic data sharing. Only the numerical bound requested in part $2$ will be graded as the final answer.",
            "solution": "The problem as stated is valid. It is scientifically grounded in the well-established principles of data privacy and medical informatics, specifically the concept of $k$-anonymity. The problem is well-posed, objective, and contains all necessary information to derive the requested upper bound and provide the subsequent explanation.\n\nThe solution proceeds in three parts as requested by the problem statement.\n\n1) Derivation of the tightest upper bound on re-identification probability.\n\nThe problem requires the derivation to start from fundamental definitions. The core concepts are $k$-anonymity and the prosecutor threat model.\n\nThe dataset is partitioned into equivalence classes based on the quasi-identifiers (QIs). An equivalence class is a set of records that are indistinguishable from one another based on their QI values. In this problem, the QIs are {age, sex, ZIP$3$}.\n\nThe problem states that the dataset is made $k$-anonymous with $k=20$. The specific application is defined as: \"every combination of age, sex, and ZIP$3$ appearing in the dataset occurs in at least 20 records.\" This directly translates to the statement that the size of any equivalence class, which we can denote as $|C|$, must be at least $k$.\n$$|C| \\ge k$$\n\nThe prosecutor threat model assumes an adversary has specific knowledge about a target individual. The adversary knows:\n(a) The target individual is present in the released dataset.\n(b) The target's exact values for the quasi-identifiers {age, sex, ZIP$3$}.\n\nLet us consider a target individual, $T$. The adversary uses the known QIs of $T$ to identify the unique equivalence class, $C_T$, to which the target $T$ belongs. Since the adversary knows $T$ is in the dataset, $T$ must be one of the records in $C_T$.\n\nWithin the equivalence class $C_T$, all records have identical QI values. Therefore, from the adversary's perspective, any of the $|C_T|$ records in the class could be the target $T$. Without any additional information, each record in $C_T$ is an equally likely candidate for being the target.\n\nThe probability of correctly re-identifying the target $T$, denoted as $P(\\text{re-id})$, is the reciprocal of the number of individuals in the target's equivalence class:\n$$P(\\text{re-id}) = \\frac{1}{|C_T|}$$\n\nThe problem asks for the tightest upper bound on this probability. To find the maximum possible value of $P(\\text{re-id})$, we must find the minimum possible value for its denominator, $|C_T|$.\n$$\\max(P(\\text{re-id})) = \\frac{1}{\\min(|C_T|)}$$\n\nFrom the definition of $k$-anonymity provided, the size of any equivalence class is guaranteed to be at least $k$.\n$$\\min(|C_T|) = k$$\n\nSubstituting this minimum size into the expression for the maximum probability gives the tightest upper bound:\n$$P_{\\text{max}}(\\text{re-id}) = \\frac{1}{k}$$\n\nThis bound is \"tight\" because it is possible for an equivalence class to have exactly $k$ members. In such a scenario, the re-identification probability for an individual in that class would be exactly $\\frac{1}{k}$. The probability cannot be greater than $\\frac{1}{k}$ because, by definition, no equivalence class can have fewer than $k$ members.\n\n2) Evaluation of the bound for $k=20$.\n\nThe problem specifies a value of $k=20$. Substituting this into the derived upper bound gives:\n$$P_{\\text{max}}(\\text{re-id}) = \\frac{1}{20}$$\nAs a decimal number, this is:\n$$P_{\\text{max}}(\\text{re-id}) = 0.05$$\n\n3) Explanation of increased risk from linkage to external registries.\n\nThe upper bound of $\\frac{1}{k}$ is valid only under the assumption that the adversary's knowledge is limited to the quasi-identifiers and the fact that the target is in the dataset. Linkage attacks violate this assumption by introducing external information.\n\nAn adversary can link the $k$-anonymous dataset with an external, publicly available registry (e.g., voter rolls, public records) that also contains the same quasi-identifiers: {age, sex, ZIP$3$}.\n\nLet us reconsider the target's equivalence class, $C_T$, in the medical dataset, for which we know $|C_T| \\ge k$. An adversary can consult an external registry and find the set of all individuals, $E$, who share the target's QIs. The adversary knows that the target must be a member of both the equivalence class from the medical data and the set of real-world individuals from the external registry. Therefore, the true set of possible candidates for the target is the intersection of these two sets, $C'_T = C_T \\cap E$.\n\nThe size of this new, refined equivalence class is $|C'_T|$. Since $C'_T$ is a subset of $C_T$, its size must be less than or equal to the size of $C_T$:\n$$|C'_T| \\le |C_T|$$\n\nThe new re-identification probability for the adversary is $P'(\\text{re-id}) = \\frac{1}{|C'_T|}$. Because $|C'_T| \\le |C_T|$, the new probability is greater than or equal to the original probability:\n$$P'(\\text{re-id}) \\ge P(\\text{re-id})$$\n\nCrucially, the linkage attack can effectively reduce the equivalence class size, possibly to a value less than $k$. For example, if an equivalence class of size 20 in the study data ($|C_T| = 20$) is linked against voter records, and only 3 individuals in those records match the QIs, the effective equivalence class size shrinks to $|C'_T|=3$. The re-identification probability for the target increases from $\\frac{1}{20}$ to $\\frac{1}{3}$. In a worst-case scenario, the intersection could contain only one individual ($|C'_T|=1$), leading to certain re-identification with a probability of 1.\n\nThis possibility has profound ethical, legal, and social implications (ELSI):\n- **Ethical**: The release of data, even if anonymized according to a standard like $k$-anonymity, may fail to uphold the ethical duty of protecting participant confidentiality if the context of publicly available information is ignored. This can lead to harm, such as insurance or employment discrimination, if sensitive genomic data is revealed.\n- **Legal**: Legal frameworks like HIPAA (Health Insurance Portability and Accountability Act) in the U.S. or GDPR (General Data Protection Regulation) in Europe define standards for data de-identification. A dataset that is re-identifiable via linkage attacks may not meet these legal standards, placing the institution in legal jeopardy. The concept of \"de-identified\" is legally interpreted in the context of what information is available to an anticipated recipient.\n- **Social**: The promise of confidentiality is foundational to public trust in research. High-profile cases of re-identification can erode this trust, making individuals reluctant to participate in future genomic studies. This would severely hamper scientific progress that relies on large-scale data sharing. The risk of linkage attacks thus creates a fundamental tension between the social benefit of open science and the individual's right to privacy.",
            "answer": "$$\\boxed{0.05}$$"
        }
    ]
}